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REGULATION OF BONE BY THE MTORC1 PATHWAY IN OSTEOCLASTS 
AND OSTEOCYES 
MOLLY FLYNN ZGODA 
 
ABSTRACT 
 
 Bone is a highly dynamic organ system comprised of various cell types that are 
constantly working to maintain the health and stability of bone.  The main cells involved 
are the osteoblasts that form bone, the osteoclasts that degrade bone, and the osteocytes 
that act as sensors of the microenvironment and coordinate a response.  An imbalance of 
the interactions between the cell types can potentially result in pathological states in bone 
at the microscopic level that can then affect the entire skeleton.  Moreover, a number of 
genetic mutations can also lead to pathogenic changes in bone.  An example of such is the 
development of sclerotic bone lesions in patients with the disease tuberous sclerosis 
complex.   
 Tuberous sclerosis complex, or TSC, is an autosomal dominant disorder affecting 
approximately 1.5 million people worldwide.  It is caused by a mutation in one of the genes 
encoding either member of the TSC1-TSC2 complex.  Molecularly, TSC1-TSC2 
negatively regulate the mechanistic target of rapamycin (mTOR) kinase in the mutli-
protein complex mTORC1.  Activation of mTORC1 leads to an upregulation of protein 
synthesis and cell growth.  Tuberous sclerosis patients are heterozygous for TSC1 or TSC2, 
and post-natal loss of the second allele results in the development of multiple, benign, 
tumor-like hamartomas in various organ systems, most notably affecting the brain, kidneys, 
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lungs, skin, and heart.  Additionally, CT scans of patients reveal multiple loci of dense, 
compact bone termed sclerotic bone lesions.  The bone lesions were most commonly seen 
in the posterior elements of the vertebrae and while they are asymptomatic, a remarkably 
high frequency of patients express them.   
To further investigate and better understand the mechanisms of tuberous sclerosis 
complex in bone, we analyzed a mouse model with heterozygous deletion in Tsc2.  Initial 
examination showed the Tsc2+/- mice recapitulated tumors in various organ systems, most 
notably the kidney, and presented bone lesions in the pelvis and elements of the vertebrae.  
To further investigate the mechanism driving the disease state, we used a Cre driver thought 
to be specific for osteoclast (Cathepsin K-Cre, or Ctsk-Cre) to selectively delete Tsc2. 
Cathepsin K-Cre; Tsc2fl/fl  mice exhibit a remarkably high bone mass.  This study examined 
three specific aspects of this high bone mass phenotype.  First, we sought to verify that the 
increased bone mass caused by Ctsk-Cre driven Tsc2 deletion  was dependent on  mTORC1 
upregulation.  This was done by generating Ctsk-Cre;Tsc2fl/fl  mice lacking Raptor, a 
mTORC1 component essential for function.  Next, we investigated the cell of origin driving 
the increase bone density by utilizing additional Cre drivers specific for osteoclasts and 
osteocytes.  Additionally, we used radiation chimeras to assess if donated wild type cells 
could rescue the observed phenotype.  We lastly explored the role of a secreted signaling 
molecule,  CTHRC1, that has been proposed as a candidate to mediate osteoclast-osteoblast 
interaction, in the high bone mass phenotype of Ctsk-Cre;Tsc2fl/fl   mice.  
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Selective deletion of Tsc2 in bone cells provides an excellent model to investigate 
pathways regulating bone mass and strength and may provide new candidate targets for 
treating diseases of low bone mass, such as osteoporosis.   
		 viii	
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INTRODUCTION 
1.1 Bone Biology: An Overview 
1.1.a Osteoblasts and Osteocytes 
There are three main cell types that are essential to bone- osteoblasts, osteoclasts 
and osteocytes.  Mononuclear osteoblasts (OBs) are the primary bone-forming cells.  OBs 
are derived from bone marrow stromal cells (BMSCs) and proceed through several stages 
of differentiation including mesenchymal progenitors, preosteoblasts and mature 
osteoblasts.  The stages can be distinguished from one another depending on the 
transcription factor the cell produces at each.  Preosteoblasts express RUNX2 and Osterix 
(OSX) while mature OBs produce osteocalcin (OCN)1.  The transcription factor RUNX2 
plays an essential role in the differentiation from BMSCs to OBs as its deletion results in 
non-mineralized bone and a lack of mature OBs2.  Active and fully differentiated OBs 
function by secreting osteoid, the non-mineralized bone matrix.  The bone-forming life-
span of an active OB is about 3 months.  Following their active lifetime, OBs can proceed 
to one of four different outcomes- they can become embedded in the matrix as osteocytes, 
become inactive bone-lining cells, undergo apoptosis, or transdifferentiate to produce 
chondroid.  Approximately 5-20% of OBs are fated to become osteocytes (OCytes), the 
most abundant type of bone cell3.  The transition from OB to OCyte includes several 
morphological and functional changes that render the former OBs inactive in terms of bone 
secretion.  Instead, OCytes play an integral role in maintaining bone homeostasis.  
Morphologically, the cuboidal OBs become buried in lacunar spaces within the bone matrix 
	
	
	
	
	
	
2	
and evolve into the dendritic-like shape of OCytes.  The development of multiple 
cytoplasmic projections creates an intricate lacunar-canaliculi network (LCN) of 
communication, connecting the OCyte to neighboring cells as well as those on the bone 
surface.  To maintain bone homeostasis, the OCytes sense mechanical stimulation and 
loading (or lack thereof) and use the LCN to connect with OBs and OCs to orchestrate the 
proper response4,5.  Recent data has also suggested that OCytes are also sensitive to bone 
oxygen levels and coordinate the suitable reaction to its fluctuations6,7. 
 
 
 
 
 
 
 
 
 
1.1.b Osteoclasts 
The only cells known to degrade bone are the giant, multinucleated osteoclasts 
(OCs) that are derived from myeloid hematopoietic precursors.  The osteoclast precursors 
Figure 1. Model of the transition from osteoblast to osteocyte. The schematic above depicts the 
differentiation of the osteoblast as well as its transition to an osteocyte. The cells labeled (1) and (2) are 
preosteoblasts, with the former at an earlier stage than the latter. (3) is very basic representation of a mature, 
active OB secreting osteoid while attached to the bone surface. (4), (5), and (6) depict the transition stages 
of OB to OCyte, as the OB slowly becomes entrapped in the matrix. An OCyte and a basic LCN is seen with 
cell (7), as its projections are extending toward other cells and the surface. (8) shows an older OCtye, 
characterized by its decrease in projection as well as its location deep in the matrix3 
	
	
	
	
	
	
	
3	
(OCPs), located in the bone marrow, proliferate and are then recruited by various 
transcription factors to travel to sites of bone remodeling.  There, the OCPs are stimulated 
to become mononuclear tartrate-resistant acid phosphate (TRAP)-positive cells termed 
preosteoclasts (preOCs).  Multiple preOCs fuse together to become active, mature OCs8,9.  
The correct and complete differentiation of OCs requires the presence of two distinct 
cytokines- the macrophage colony stimulating factor (M-CSF) and receptor activator of 
NF-𝜅B ligand (RANKL).  M-CSF promotes OC formation and differentiation while RANKL 
binds to its counterpart, the receptor activator of NF-𝜅B (RANK) which is expressed by 
various cells including osteoblasts.  The RANKL/RANK interaction activates the NF-𝜅B 
signaling pathway that is crucial to the OC function of bone resorption10,11.  Osteoprotegrin 
(OPG), produced by osteoblast lineage cells, acts as a decoy receptor for RANKL, thereby 
blocking its interaction with RANK and inhibiting OC differentiation and activity12.  The 
resorptive function of OCs is an energy-demanding process that requires their attachment 
to the bone surface.  Once attached, cytoskeleton structures called podosomes reorganize 
to form a stable sealing zone that separates the area of active resorption from the rest of the 
bone microenvironment.  Beginning the breakdown of matrix, OCs first secrete the acid 
HCl to degrade the inorganic phase of bone that consists mainly of hydroxyapatite.  
Vesicles of cathepsin K (CTSK) are released from OCs via exocytosis to break down the 
remaining organic components of bone13,14,15.  CTSK plays an additional role in OC 
function by contributing to the formation of the ruffled border, a morphological change 
that occurs on the surface of OC in contact with the bone surface. The exocytosis of CTSK 
as well as the endocytosis of the bone degradation products manipulate the actively 
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resorbing cell surface in such a way, creating the ruffled appearance16.  The border provides 
additional protection for the surrounding bone from the degrading components HCl and 
CTSK.    
 
 
 
 
 
 
 
 
 
 
 
1.1.c Bone formation and remodeling 
There are two main mechanisms of bone modeling in skeletal development- 
intramembranous ossification and endochondral ossification.  The former contributes 
primarily to the formation of the skull and cranial bones while the latter gives rise to other 
bones of the skeleton18.  An explicit distinction between the two modes of bone formation 
Figure 2: The RANK/RANKL/OPG system. The necessity of RANK, RANKL, and OPG for differentiation 
of OCs can be seen in the above diagram.  The RANKL located on OBs interacts with its receptor, RANK, 
on the surface of preOCs. This interaction recruits TRAF6, an activator of the NF-𝜅B pathway.  NF-𝜅B 
responds by stimulate the generation of osteoclastogenic genes to increase OC differentiation. OPG has the 
ability to competitively block RANKL binding to RANK, therefore inhibiting the entire pathway17.    
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is that endochondral ossification involves the replacement of a cartilage model while 
intramembranous does not.  In the cartilaginous-lacking intramembranous ossification, the 
differentiation of OBs from mesenchymal cells occurs via osteoprogenitor cells.  The 
mature OBs can then begin the deposition of bone formation.  In endochondral ossification, 
bone formation occurs in a series of sequential coordinated steps.  Instead of differentiating 
immediately into OBs, the mesenchymal cells first condense and differentiate into 
chondrocytes to form a cartilage mold that is then ultimately replaced by bone18,19.   
Bone and the skeleton play crucial roles in protection, locomotion and stability of 
the body. To meet such mechanical demands, bone tissue is constantly being remodeled at 
the microscopic level.  This action is coordinated by the presence of Bone Multicellular 
Units (BMUs), temporary structures that house the various cell types required for the 
remodeling process20.  The continuous activity of multiple BMU’s at differing bone sites 
happens to such a degree that the entire skeleton is replaced approximately every ten 
years21.  This concerted action of OCs removing old bone as OBs form new, fresh tissue is 
imperative to the maintenance of a healthy, stable skeleton that translates to a healthy body 
system.  A pivotal event that stimulates remodeling is OCyte apoptosis at focal areas of 
microdamage due to abnormal mechanical loading or normal daily activity.  At standard 
conditions of non-remodeling areas of bone, the OCytes produce the glycoprotein 
sclerostin that inhibits OB activation and OCP recruitment.  Apoptosis of OCytes due to 
load or damage decreases the amount of sclerostin being produced, thereby removing the 
inhibition of BMU recruitment to the site of microdamage22.  The complementary action 
of the bone cells is maintained by osteoclast:osteoblast coupling, suggesting that the 
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functions of OCs extend beyond bone resorption.  Specifically, recent evidence supports 
the existence of secreted OC-derived coupling factors termed clastokines23. 
1.1.d CTHRC1 and other clastokines 
The highly-concerted actions in the perpetual process of bone remodeling suggests 
an interaction between the components involved for regulation.  Awareness of the 
osteoclast:osteoblast coupling led to the identification of clastokines, OC-derived 
cytokines that have been shown to contribute to the necessary coupling in vivo.  Three 
specific examples are sphingosine-1-phosphate (S1P), complement cascade component 3a 
(C3a), and collagen triple helix repeat containing 1 (CTHRC1)23.  S1P is the product of 
sphingosine kinase 1 (SPHK1) and expression of both is stimulated during OC 
differentiation.  Studies concerning their role in bone remodeling have found that S1P 
promotes the differentiation of OB by binding to its receptor, S1PR, located on the surface 
ob OB.  C3a is part of the complement system involved in systemic defense produced in 
the liver.  OCs promote the cleavage of the complement cascade component C3 into its 
product C3a, which then binds its C3aR expressed on OB lineage cells.  Similar to S1P, 
binding of C3a to its receptor promoted OB differentiation, thereby linking OC resorption 
and OB response20, 23.  CTHRC1 was initially discovered as a novel gene expressed in active 
fibroblasts of remodeling tissues recovering from injury24.  This unique gene encodes a 
circulating hormone that has been found to play key roles in adipogenesis, body 
composition, and voluntary physical activity25, 26.  Several studies examining the role of 
CTHRC1 in bone remodeling found it to be a downstream target of bone morphogenetic 
protein-2 (BMP2).  Further investigation lead to the conclusion that CTHRC1 was induced 
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in OC following the commencement of resorption and promoted OB differentiation and 
subsequent bone formation23,27.   
 
 
 
 
 
 
 
 
1.2 The mTOR Pathway 
1.2.a mTOR structure and function 
Mechanistic target of rapamycin (mTOR) is a serine/threonine protein kinase that 
acts a key regulator of major cellular functions in response to various environmental 
signals, nutrients, and hormones.  The kinase is member of the phosphoinositide-3-OH 
(P13K)-related kinase family which are widely recognized as primary regulators of cellular 
growth and metabolism28,29.  mTOR is made up of two functionally separate protein 
complexes, mTOR Complex 1 (mTORC1) and mTOR Complex 2 (mTORC2), that differ 
in their upstream regulators and downstream targets as well as in their sensitivities to the 
cellular subtypes [17,18]. In this section, osteoclast-cen-
tered couplin  mec anisms are reviewed.
Release of matrix-derived growth factors (Figure 1A)
Initial efforts to identify osteoclast-dependent coupling
mechanisms focused on growth factors embedded within
bone matrix. Transforming growth factor b1 (TGFb1) re-
leased during osteoclast culture on bone induces the mi-
gration of mesenchymal stem cells (MSC) in vitro, and
MSC migration to bone surfaces is reduced in Tgfb1!/!
mice [19]. Similarly, insulin-like growth factor 1 (IGF1)
liberated from bone by osteoclastic resorption is proposed
to promote osteogenic differentiation [20]. Release of ma-
trix-derived growth factors is also invoked as a mechanism
supporting growth of bone metastases (Box 1). The de-
creased osteoblast numbers and reduced bone mass in
TGFb1-deficient mice, and in mice with an osteoblast-
specific deficiency of insulin-like growth factor receptor 1
(IGFR1), suggest that matrix-derived TGFb1 and IGF1 are
important coupling mediators. Moreover, elevated osteo-
clast numbers in the subchondral bone of mice with exper-
imentally induced osteoarthritis was associated with an
increase in local TGFb activity [21]. This increased
TGFb was linked to the subsequent formation of islets
MCSF
RANKL
OCP
OC
RANK-
RANKL
Ephrins
Eph
(C)
(A)
(B)
MCSF
RANKL
Pre-OB Bone lining cells
OCP
OC Clastokines
Migra!on
Prolifera!on
Differen!a!on
OB progenitors
MCSF
RANKL
TGFβ
IGF1
OB progenitors
Pre-OB Bone lining cells
OCP
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Mature OB
Pro-differen!a!on
Pro-survival
Osteoid Nascent
Osteocyte
Bone Osteocyte
TRENDS in Molecular Medicine
Figure 1. Osteoclasts–osteoblast interactions in the basic multicellular unit (BMU). (A) Osteoclasts (OC) differentiate from OC precursors (OCP) under the influence of MCSF
and RANKL produced by osteoblast (OB) lineage cells including osteocytes. As OCs create a resorption pit, growth factors, including TGFb and IGF1, are released from the
bone matrix. These growth factors may recruit mesenchym l steoblast progenitors and promote th ir differentiati n into mature cells that secrete osteoid to fill the area of
resorbed bone. Some OBs differentiate further into matrix-embedded osteocytes. (B) OCs produce several clastokines (Table 1) that may recruit OB progenitors and
promote their proliferation and differentiation. (C) Cell–cell contact mechanisms may also mediate OC-OB communication. Bidirectional signaling from OC ephrins and OB
Eph receptors, and reverse signaling through RANKL on OBs, have both been invoked. Abbreviations: IGF1, insulin-like gr wth factor 1; MCSF, macrophage colony
stimulating factor; RANKL, receptor activator of NF-kB ligand; TGFb, transforming growth factor b.
Review Trends in Molecular Medicine August 2014, Vol. 20, No. 8
450
Figure 3: Osteoclast:osteoblast coupling in the bone multicellular unit during remodeling. The diagram 
above shows an example of the interaction between osteoclasts (OC) and osteoblasts (OB) during bone 
remodeling. The OCs are derived from osteoclast precursors (OCP) with stimulation from MCSF and 
RANKL. As they actively resorb bone at a site of remodeling, they release clastokines that then recruit the 
migration, proliferation, and differentiation of OB progenitors into pre-OB. This schematic is a model of the 
osteoclast:osteoblast coupling necessary to maintain healthy bone23.  
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molecule rapamycin.  mTORC1 is comprised of the regulatory-associated protein of 
mTOR (Raptor) and is sensitive to rapamycin while mTORC2 contains the rapamycin-
insensitive companion of mTOR (Rictor) and is resistant to rapamycin30,31.  Functionally, 
mTORC1 is crucial in regulating cell growth and metabolism by activating protein 
translation and inhibiting autophagy.  mTORC2 mainly controls growth factor signaling, 
cell survival and proliferation32.  
 
 
 
 
 
 
 
 
 
 
 
 
	
	
Figure 4. Upstream regulatory pathway of mTOR and TSC1-TSC2. The diagram displays the various 
sources of regulation of the mTOR pathway including the TSC1-TSC2 complex.  Generally, the TSC1-TSC2 
complex in activated by a decrease in nutrients or energy resulting in the inhibition of mTOR30.   
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1.2.b TSC1-TCS2 complex 
A vital upstream regulator of mTOR is the TSC1-TCS2 complex consisting of the 
genes TSC1 and TSC2 that code for harmartin and tuberin respectfully.  The complex acts 
as a GTPase-activing protein (GAP) specifically targeting the Ras homolog enriched in 
brain (RHEB) gene.  GTP-bound RHEB stimulates mTORC1 directly to active its 
downstream signals.  The TSC1-TCS2 complex accelerates the GTP hydrolysis of RHEB 
converting its active GTP-bound form to its inactive GDP-bound form, thereby inhibiting 
the action of mTOR1,33.  
The TSC1-TSC2 complex is subject to regulation of its own by several factors and 
pathways including extracellular signaling-regulated kinase (Erk), AMP-activated kinase 
(AMPK), glycogen synthase kinase 3 (GSK3) and P13K signaling pathway.  Erk 
phosphorylation of TSC1-TSC2 causes the two genes to dissociate, resulting in inhibition.  
Similarly, Akt-mediated phosphorylation of TSC2 can occur via the PI3K signaling 
pathway activated by the binding of growth factors (GF) or insulin to their receptors.  This 
specific phosphorylation either disrupts the interaction between TSC1 and TSC2 or 
accelerates its degradation.  Regardless, the TSC1-TSC2 complex is inhibited by both Erk 
phosphorylation and P13K signaling leading to the uninhibited activation of mTOR.  The 
main activators of the complex are AMPK and GSK3, stimulated by a decrease in energy 
or glucose.  In this situation, the upregulation of the TSC1-TSC2 complex negatively 
regulates mTOR and reduces protein synthesis30,34,35.  The cell cycle regulatory component 
p53 plays dual roles with the mTOR pathway as both a regulator and a target.  Upstream, 
p53 upregulates the expression of TSC2 thus inhibiting mTOR activity.  The downstream 
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effect of mTOR on p53 is by an unknown mechanism that warrants further investigation36.  
In summary, the TSC1-TSC2 complex is largely activated in response to the need for more 
energy and nutrients and activates mTORC1 to promote cell growth.   
TSC1-TSC2-independent regulatory pathways of mTOR also exist.  One such 
example is stimulation or inhibition of mTORC1 by amino acids.  More specifically, a 
study examined the effect of high glutamine levels to find that it inhibited mTORC1 
activity37.  A visual schematic of regulation details of both mTOR and the TSC1-TSC2 
complex can be seen in Figure 4.   
1.2.c Downstream Targets of mTOR 
 The best characterized and most understood downstream effectors of mTOR are S6 
kinase 1 (S6K1) and eukaryotic initiation factor 4E-binding protein-1 (4E-BP1)1.  Once 
activated by mTOR, S6K1 phosphorylates the ribosomal protein S6 to mediate the 
regulation of cellular size by upregulating protein synthesis and cell growth.  This 
component is also capable of its own regulation by engaging in a negative feedback loop.  
In addition to activating S6, S6K1 inhibits the insulin receptor function therefore slowing 
P13K-AKT signaling, an inhibitor of TSC1-TSC2.  This decrease in signaling leads to a 
decrease in mTOR to ensure no abnormal cell growth takes place.  4E-BP1, without mTOR, 
binds and inhibits the eukaryotic initiation factor 4E (eIF4E).  Phosphorylating by mTOR 
releases this inhibition, allowing eIF4E to initiate translation, therefore increasing cell 
growth30.  Beyond these two targets that aim to increase cell growth by enhanced protein 
synthesis, mTORC1 activity plays a very large role in the regulation of autophagy, a 
lysosomal degradation process that aims to remove damaged and aged organelles.  
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mTORC1 directly inhibits the degradation by blocking formation of the autophagosomal 
membrane, a step necessary for autophagy to occur.  The presence or absence of free amino 
acids plays a large role in regulating mTORC1’s effect on autophagy as the former situation 
activates mTORC1 therefore suppressing autophagy while the latter does the opposite32,38.  
 
 
 
 
 
 
 
1.2.d mTOR Effects on specific bone cells 
 The specific role of the mTOR pathway on bone cells has been studied in several 
and varying situations, but the results reported are controversial and require additional 
attention.  mTOR’s contribution to the proliferation and differentiation of OBs has led to 
numerous conclusions.  A 2015 study reported that mTORC1 activation is required for 
preOB proliferation, but its inactivation is then necessary for their differentiation into 
active, mature OB.  Evidence supporting this claim was presented as mice with a deletion 
of Tsc1 in preOB using an Osx Cre driver.  The resulting mice exhibited immature woven 
bone due to increased proliferation but decreased differentiation1.  An additional study 
Figure 5. Downstream targets of mTORC1. Above is a simplified schematic of a subset of downstream 
mTORC1.  The pathways of note include its simultaneous stimulation of S6K and inhibition of 4E-BP1 
resulting in increased protein synthesis and cell growth.  Additionally, its inhibition of autophagy in the 
presence of amino acids30.  
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deleted Tsc2 in mature osteoblasts using Ocn-Cre and reported a similar disorganized bone 
phenotype39.  While these investigations yield similar conclusions, studies involving the 
direct inhibition of mTOR signaling have found that it leads to the promotion and 
suppression of OB differentiation28.  This conclusion is significant because it suggests the 
role of mTOR on the OB cell lineage is dependent on the stage of differentiation the cell is 
in, complicating the investigation of mTOR as a therapeutic target.  Likewise, the effect of 
mTOR activity on OCs was also examined and it was found to play a central role in the 
differentiation and activity of the bone resorbing cells.  OC-specific deletion of Raptor 
results in ineffectual mTORC1.  Studies utilizing this genetic deletion in mice noted a 
modest increase in bone mass with decreased bone resorption8,40, supporting the claim that 
mTORC1 promotes the differentiation of OCs.  Despite the potentially positive effect of 
mTORC1 on OC differentiation, it has the opposite effect on OC activity.  A 2017 study 
utilized a Ctsk-Cre driver to delete the upstream Tsc1 in OC leading to upregulated 
mTORC1.  This deletion led to decreased formation of the podosome belt and sealing zone 
that is essential to the actual bone resorption of OCs.  Due to this abnormality, OC 
resorption was greatly reduced, leading to increased bone mass14.  The conflicting reports 
suggest that mTOR has various, complicated roles in the regulation of osteogenesis and 
action depending on cell type and its point in differentiation.  A 2017 study sought to 
explore mTOR’s role in bone size and quality.   The utilization of Prx1-Cre, Dermo1-Cre, 
Osc-Cre, and Ctsk-Cre was performed to specifically ablate Tsc1 in MSCs, monocytes, 
OB, and OCs respectively.  The study reported mTOR regulates bone quality by the 
suppression of OC bone resorption and bone size by MSCs41.  Overall, the specific details 
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of mTOR regulation warrant further investigation as it serves as a potential therapeutic 
target for treatment of several osteopathologies.   
1.3 Conditions associated with pathologic bone lesions 
1.3.a. Tuberous Sclerosis Complex 
A relevant clinical example involving mutations in the mTOR pathway is Tuberous 
Sclerosis Complex (TSC).  This autosomal dominant disease results from a pathogenic 
variant in either the TSC1 or TSC2 gene causing hyperactive mTOR expression.  It is 
reported that TSC has a birth incidence of 1 in 6000 and affects approximately 1.5 million 
people worldwide.  However, the varying degrees of symptom severity lead many potential 
cases to remain undiagnosed.  Clinical manifestations begin early in life as patients are 
most frequently diagnosed under the age of 15 months42,43,44.  Clinically, TSC presents with 
the proliferation of multiple benign, non-invasive, tumor-like lesions termed harmartomas 
that appear in various organ systems but most frequently in the brain, kidney, skin, lung, 
and heart44.  In 2012, the International Tuberous Sclerosis Complex Conference outlined 
the major and minor clinical features that are to be considered diagnostic criteria for TSC.  
To affirm a definitive TSC diagnosis, two major features must be presented or, 
alternatively, one major and two minor clinical features which are all listed in Table 1.  
Approximately 80% of TSC subjects develop renal angiomyolipomas (AMLs) that elicit 
the associated risk of acute bleeding and ultimately renal failure, the leading cause of death 
is adult TSC patients42.  Supplementary to the list of accepted diagnostic criteria, additional 
clinical manifestations can also be present.  An example of such is focal sclerotic bone 
lesions (SBLs)- a foci of dense, compact bone when observed on computerized tomography 
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(CT) scans.  SBLs are a very frequent occurrence in TSC patients, but are asymptomatic 
thus they are absent from the diagnostic criteria.  Moreover, they are usually only 
discovered by CT scan when investigating other complications of TSC such as 
lymphangioleiomyomatosis (LAM) in the lung45.  A genotype-phenotype study examined 
the possibility of a correlation between the specific mutation of the patient and the presence 
of SBLs as well as their general distribution in the skeleton.  After genotyping and 
analyzing CT scans of a substantial population of diagnosed TSC patients, it was reported 
a high frequency patients presented with SBLs regardless if their mutation was in TSC1 or 
TSC2.  It was additionally noted that the SBLs were preferentially located in posterior 
elements of the vertebrae, primarily in pedicles and laminas.  While they are asymptomatic, 
it is essential to characterize SBLs of TSC to avoid a misdiagnosis of osteoblastic 
metastases46. 
 
 
Major Clinical Features Minor Clinical Features 
Hypomelanotic Macules (≥3, at least 5mm 
diameter) 
“Confetti” lesions of the skin 
Angiofibromas (≥3) or Fibrous Cephalic Plaque Dental Enamel Pits (≥3) 
Ungual Fibromas (≥2) Intraoral Fibromas (≥2) 
Shagreen Patch Retinal Achromic Patch 
Retinal Hamartomas (multiple) Renal Cysts (multiple) 
Cortical Dysplasia (≥3, including tubers and brain 
     white matter radial migration lines) 
Nonrenal Hamartomas 
Sub ependymal Nodules  
Sub ependymal Giant Cell Astrocytoma  
Cardiac Rhabdomyoma  
Lymphangioleiomyomatosis (LAM)  
Angiomyolipomas (≥2) (AMLs)  
Table 1. Diagnostic criteria of TSC 
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1.3.b Additional osteopathies 
Maintaining the balance between bone resorption and formation is crucial for a 
healthy, stable skeleton.  In the event that this homeostasis is disrupted, certain conditions 
can result such as osteoporosis or osteopetrosis.  The musculoskeletal disease osteoporosis 
occurs following an imbalance in bone remodeling, when resorption greatly exceeds 
formation.  The millions of patients suffering from this experience a deterioration of the 
bone microarchitecture, increasing their risk of fracture as well as mortality21,28,54.  An 
additional example cluster of genetic bone diseases are ostepetroses, rare heterogeneous 
disorders that display increased bone mass due to irregular OCs.  The osteopetroses can 
further be classified into two main subgroups depending on the supply of OCs present.  The 
osteoclast-rich osteopetroses have normal to high OC numbers but their resorptive function 
is impaired.  Conversely, osteoclast-poor osteopetroses show no OCs, therefore making 
bone resorption unattainable55.  Each subgroup results in an inability for bone resorption 
by OCs leading to increased bone mass.  Paradoxically, this high-density bone mass has 
extremely poor quality and increased fragility because it is non-remodeled56 
Several orthopedic pathologies are due to the interaction between bone and the 
immune system along with disturbances in microenvironment homeostasis.  One such 
example is the age-related disease osteoarthritis (OA), the most common type of arthritis.  
OA is defined as the destructive degeneration of joints and articular cartilage that cause 
increasingly high amounts of pain and swelling, limiting the physical ability of patients.  
Associated risk factors include genetic predisposition, gender, age, obesity, and previous 
trauma or injury.  Despite the exceedingly high number of patients with this joint 
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degeneration, as well as its debilitating and painful effects, the exact pathology and 
mechanisms of OA are still uncertain47,48  In contrast to OA, rheumatoid arthritis (RA) is 
an autoimmune disease affecting approximately 1% of the world’s population that causes 
the chronic inflammation and joint destruction49,50.  The most common sites affected are 
the interphalangeal and metacarpophalangeal joints of the hand or the joints of the knee, 
both vital to even the simplest of everyday activities51.  Similar to OA, the precise 
mechanism driving the effects seen from RA are not entirely clear.  It is thought that the 
pro-inflammatory cytokines resulting from the onset of the autoimmune disorder are 
responsible for the joint damage as their upregulation promotes enhanced OC 
differentiation adjacent to the site of inflammation.  The overactive OC activity leads to 
increased bone resorption and erosion, providing the destruction of not only the joint but 
of the surrounding tissue as well52,53.   
1.3.c Treatment 
 Despite the fact that SBLs are seen in approximately 80-90% of TSC patients, they 
are asymptomatic and cause no direct distress.  However, the overactive mTOR that causes 
the SBLs also affects the other manifestations of TSC that do result in major clinical issues.  
Thus, therapies to treat symptoms and slow disease progression often aim to inhibit this 
overexpression of mTOR.  Rapamycin, also known as sirolimus, is a commonly used 
antifungal immunosuppressive drug commonly used to prevent allograft rejection 
following an organ transplant43.  Molecularly, it a specific inhibitor of mTORC1 and its 
downstream targets, therefore leading to a decrease in cell proliferation and potentially 
reducing some features of TSC.  In terms of osteogenesis, rapamycin can downregulate the 
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expression of RANKL, M-CSF, and tumor necrosis factor 𝛼 (TNF𝛼) as well as inhibit the 
release of inflammatory factors57.  Together these effects result in the suppression of 
proliferation and differentiation of osteoclasts.  However, several studies have reported 
both positive and negative results in investigating the effect of rapamycin on osteogenesis.  
These differences in conclusions may be due to differences in cell type or its stage of 
differentiation at the time of the study or the experimental conditions35.  Regardless, 
rapamycin’s role as a mTOR-specific inhibitor is a reason for potential therapeutic 
targeting and should be further investigated.   
 Osteoporosis results from an imbalance of skeletal homeostasis as bone resorption 
greatly exceeds its formation.  The current primary treatment course of these disorders is 
anti-resorptive therapy, namely bisphosphonates and denosumab.  Both aim to inhibit bone 
resorption by decreasing the number of OCs present.  Specifially, bisphosphonates increase 
the incidence of OC apoptosis while denosumab impedes the differentiation of macrophage 
precursors into mature OCs.  Unfortunately, these treatments are not ideal.  Several adverse 
effects have been reported as a result of bisphosphonate therapy including rash, weight 
loss, sciatica, and asthma.  Additionally, the inhibition of resorption by way of decreasing 
the OC number also affects bone formation.  As stated prior, OCs interact with OCs during 
resorption to influence the formation of bone where it was just resorbed.  This lack of signal 
affects the entire remodeling process and further complicates bone health15,28.     
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1.4 Aims and Hypothesis 
Here, we generated CtskCre;Tsc2 mice to analyze how the upregulation of mTOR 
due to specific loss of Tsc2 in OC may lead to the formation of the sclerotic bone lesions 
seen in TSC.  Phenotypically, we observed a large increase in bone mass.  We initially 
hypothesized this increase in bone mass due to dysfunctional OCs with the mechanism 
behind the faulty OCs being either the absence or low number of OCs actually present or 
an inability to properly resorb bone.  In vitro and in vivo testing determined our initial 
thoughts incorrect.  Furthermore, an increase in bone formation in CtskCre;Tsc2fl/fl mice 
suggested that OB activity was not normal to low as we had first thought, but was enhanced.  
Additionally, we hypothesized that the increase in bone mass occurred by way of deletion 
of Tsc2 increasing mTOR acitivity.  Generation and analysis CtsCre;Tsc2;Raptor mice 
provided evidence supporting our claim.   Our aim then became to identify the cell of origin 
driving the accretion of the high bone mass.  Additionally, we sought to look at the possible 
presence and contribution that OC-derived cytokines may have on the remodeling process 
and the interaction between bone cells.  
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METHODS 
2.1 Mice 
 CtskCre;Tsc2fl/fl mice on the C57BL/6NJ background were generated by crossing 
CtskCre mice to Tsc2 fl/fl mice.  The CtskCre mouse line was a gift from Shigeaki Kato, 
University of Tokyo, Japan.  The line has been maintained in the heterozygous state by 
backcrossing to the C57BL/6NJ line for twenty generations with CtskCre specific 
genotyping at every generation.  Cre expression was validated using a Cre reporter 58.  
Raptorfl/fl  mice (B6.Cg-Rptortm1.1Dmsa/J) were purchased from the Jackson Laboratory and 
possess loxP sites flanking exon 6 of the targeted Raptor gene.  To generate OC-specific 
knockout of Raptor, we crossed the RaptorloxP line to the CtskCre; Tsc2fl/fl line.  This 
breeding generated CtskCre;Tsc2fl/fl,Raptorfl/fl, CtskCre;Tsc2fl/fl,Raptorfl/+, and 
CtskCre;Tsc2fl/fl,Raptor+/+   littermates for comparison59.  Dmp1-Cre (B6.Cg-Tg (Dmp1-
cre/ERT2) D77Pdp/J) mice were purchased from the Jackson Laboratory.  Tsc2fl/fl mice 
were crossed to the Dmp1-Cre mice to specifically delete Tsc2 in osteocytes and generate 
Tsc2fl/fl;Dmp1-Cre+ and Tsc2fl/fl;Dmp1-Cre- littermates60.  Rank-Cre mice were obtained 
from Dr. Jae Shim at UMass Worcester as an additional strategy to achieve OC-specific 
deletion.  We bred Rank-Cre mice to Tsc2fl/fl mice to generate Rank-Cre;Tsc2fl/fl and Rank-
Cre;Tsc2fl/+ littermates61.  ROSA26mT/mG mice (B6.129(Cg)-Gt(ROSA)26Sortm1.1(ACTB-tdTomato,-
EGFP)Lou/J) were purchased from the Jackson Laboratory.  ROSAmT/mG is a cell membrane-
targeted, two-color fluorescent Cre-reporter allele62.   The Cthrc1-/-mice were a kind gift of 
V. Linder, Maine Medical Center.  The age and sex of mice included in each experiment 
are specified in the text.  Mice were housed in microisolator cages with up to 5 mice per 
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cage in specific pathogen-free animal facilities at Brigham and Women’s Hospital under 
standard 12 hour light-12 hour dark conditions.  Animals had access to standard mouse 
chow (PicoLab Mouse Diet 20 #5058, Lab-Diet) and water ad libitum.  All studies were 
performed according to institutional and NIH guidelines for care and use of laboratory 
animals and were approved by the Institutional Animal Care and Use Commit-tee of 
Brigham and Women’s Hospital.   
2.2 Micro-Computed Tomography (microCT) 
 Scanning of samples was performed with a Scanco Medical 𝜇CT-35 System and an 
isotropic voxel size of 7	𝜇m.  Analysis was performed blind to the genotype of the mouse 
sample.  Femurs were scanned in 70% ethanol with an X-ray intensity of 0.145mA, an x-
ray tube potential of 55kVp, and an integration time of 600ms.  A region beginning 
approximately 0.3 mm proximal to the growth plate and extending 1.0 mm proximally was 
selected for trabecular bone analysis.  A second region of 0.6 mm was selected at the center 
of the midshaft to represent cortical bone parameters.  An automatic as well as a manual 
contouring approach was utilized to determine the region of interest.  The manually-set 
thresholds differed between the genotype being tested and are displayed in Table 2.  Bone 
parameters including bone volume fraction (BV/TV), trabecular number (Tb.N), trabecular 
thickness (Tb.Th), trabecular separation (Tb. Sp), trabecular bone mineral density 
(Tb.BMD), cortical thickness (Ct.Th) and cortical bone mineral density (Ct.BMD) were 
calculated with the software provided by the manufacturer in addition to the generation of 
the 3-dimensional images.   
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2.3 Bone biomechanical testing 
 Biomechanical properties of the CtskCre;Tsc2fl/fl bone were assessed in 
collaboration with the Shefelbine lab.  Three point-bending experiments were performed 
on an Instron 5966 to compute the results in a post-processing analysis.  The study 
consisted of testing the bones of 8 male samples (5 mutant and 3 control) in a displacement 
control mode and a displacement rate of 0.01mm/s.  Load was monitored by a 50 N load 
cell and the femurs was loaded in the anterior-posterior orientation on a micro three-point 
bending set-up seen in Figure 6.  The micro three-point bending set-up includes a plunger 
radius of 0.25mm and a span length of 6 mm, seen in Figure 6.  The conclusion of the test 
was marked with a 40% load drop in each case.  A custom MATLAB code (Matlab, 
MathWorks) was used to analyze the load-displacement data for each sample. 
 
 
 
Experiment/Genotype (section) Cortical Threshold Trabecular Threshold 
Raptor (3.1.d) 420 270 
Dmp1 (3.2.a) 410 320 
Bone marrow chimera (3.2.b) 410 350 
Cthrc1 (3.3.b) 440 320 
Table 2. Manual microCT thresholds 
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2.4 ELISA for Serum CTX-I and P1NP 
 Blood samples were collected from the mice via cardiac puncture and the serum 
isolated using serum separation tubes (Becton Dickinson).  From the serum, levels of bone 
resorption marker C-terminal telopeptides (CTX-I) and bone formation marker procollagen 
type 1 propeptides (P1NP) were quantified using enzyme immunoassays 
(Immunodiagnostics Systems).  All ELISAs were read with a Synergy H1 Hybrid Reader 
(Biotek).   
2.5 Histology 
 A femur from each mouse sample was first fixed in 10% neutral buffered formalin 
for 48 hours.  The samples were then decalcified in 14% EDTA according to the procedure 
guidelines found in the Standard Dissection Procedure for Skeletal Analysis of Transgenic 
Mice. Following decalcification, the femurs were embedded in paraffin and processed 
according to the type of stain used.  For dynamic and static histomorphometry, bones were 
Figure 6. Micro three-point bending to test biomechanical bone properties. 
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fixed in serial cold 70% ethanol, emebedded in methylmethacrylate and sections analyzed 
according to standard protocols using the Osteomeasure program by Histomorphometry 
core of the Center for Skeletal Research, MGH. 
2.6  Osteoclast Cultures 
 Bone marrow and spleocytes were collected and cultured in mouse M-CSF and 
RANKL for 5 days in petri dishes (Corning, 100×10 mm) at a density of 1.2×106 cells/mL.  
The culture media was changed every 3 days.  OC differentiation was quantified after 14 
days by the standard method of staining fixed cultures for tartrate-resistant acid 
phosphatase (TRAP) activity and counting multinucleated TRAP-positive cells. TRAP 
degrades skeletal phosphoproteins including osteopontin (OPN) and is essential for the 
bone-resorptive functions of OCs. Since TRAP secreted from OCs into the extracellular 
milieu, the activity of secreted TRAP enzyme in culture supernatants was determined as a 
confirmatory assay. 
2.7 Radiation Chimera 
 Mice were lethally irradiated with 1100RAD in split dosing.  Following 12 hours 
of rest, we injected the irradiated mice via retroorbital injections with the 2x106 donor bone 
marrow cells from selected donor mice.  The irradiated cohort was then allowed to recover 
for 16 weeks in five cages separate cages housing two mice each.  For each pair of mice 
receiving wild-type or mutant donor bone marrow, the hosts were littermates.   After 
irradiation, all mice received sulfatrim antibiotic treated drinking water ad libitum.   
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2.8 Statistical Analysis 
 Statistical analysis and graphing were performed with Prism 7 (GraphPad 
Software).  Two experimental groups were compared using the Student’s t-test and more 
than two by one-way ANOVA.  
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RESULTS 
3.1 Effect of Tsc2 perturbation on bone and bone cells 
To further study the clinical implications of TSC, we analyzed the bone phenotype 
of a Tsc2 heterozyous a mouse model.  The mutant mice recapitulated benign tumors in 
some organ systems, most notably in the kidneys.  Additionally, SBLs were found to 
develop with age.  MicroCT analysis, seen in Figure 7, of 12-month-old Tsc2+/- mice 
displayed the dense, compact areas of bone indicating the presence of SBLs.  Moreover, 
these lesions were uniformly found in the pelvis and vertebrae of the mice, which are 
similarly the most common locations of SBLs in human TSC patients.  Quantification of 
the data identified the incidence of bone lesions in the mutant Tsc2+/- mice compared to the 
wild type control mice, Tsc2+/+.  There was no occurrence of SBLs at any age of the control 
mice.  In the mutant mice with deleted Tsc2, the frequency of SBLs increased with age.   
 
 
 
 
 
 
 
Figure 7. Tsc2fl/flmice developed sclerotic bone lesions as they aged. A. MicroCT analysis of the skeletons 
of control Tsc2+/+ mice and mutant Tsc2fl/+ mice showed the presence of SBLs in the pelvis and vertebrae of 
the mutant mice indicated above by the white arrows.  B. The incidence of the SBLs increased with age in 
the mutant mice while no SBLs appeared at all in the control Tsc2+/+ samples.   
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3.1.b Cathepsin K-Cre driven Tsc2 deletion results in hyperactive mTORC1 expression in 
OCs 
 To further investigate deletion of Tsc2, we generated CtskCre;Tsc2fl/fl mice as 
described in Methods, with the goal of deleting Tsc2 in OCs.  As previously stated, the 
TSC1-TSC2 complex inhibits the action of mTORC1.  Therefore, we can hypothesize that 
our generated CtskCre;Tsc2fl/fl mice (hereafter referred to as Tsc2∆OC) will have 
hyperactive mTORC1.  To test this, bone marrow and splenocytes of Tsc2∆OC and Tsc2fl/fl 
mice were harvested and cultured in the presence of M-CSF and RANKL.  Differentiation 
into osteoclasts was confirmed by visualization using light microscopy. Western blotting 
for pS6K and total S6K were performed to assess mTORC1 activation. CTSK levels were 
assessed as a measure of osteoclast differentiation and actin was probed as a loading 
control.  Control and Tsc2∆OC mice displayed similar levels of CTSK, a marker of OC 
maturation meaning they have a comparable number of precursors committing to the OC 
lineage.  S6K phosphorylation was used as a marker of mTORC1 activity in western blot 
analysis, as S6K is a downstream target of mTORC1.  In the analysis, pS6K specifies the 
amount of phosphorylated S6K while tS6K represents the total present.  Thus, the ratio 
pS6K/tS6K is an excellent indicator of mTORC1 activity.  The Tsc2∆OC spleen-derived 
OC lysates displayed a 2-fold increase in S6K phosphorylation compared to the littermate 
controls, seen in Figure 8.  Therefore, this provides evidence that the OC-specific deletion 
of Tsc2 results in the increase of mTORC1 as expected.     
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3.1.c Tsc2∆OC mice display high bone mass and increased resistance to fracture 
To evaluate if the Tsc2∆OC display a bone phenotype, femoral bones from cohorts 
of male and female mice were analyzed by micro-CT at 3 months of age.  Initial 
comparison of the gross body morphometry of the samples showed no difference.  The 
mutant mice were viable, fertile, and indistinguishable from the controls in length and 
weight until approximately 9 months of age (Figure 9).   
 
 
 
 
 
Figure 8. mTORC1 is overactive in Tsc2∆OC spleen-derived osteoclasts. A. Western blot analysis of 
splenic osteoclasts showed increased levels of pS6K and tS6K (markers of mTORC1 activity) in Tsc2∆OC 
mice.  The expression of Ctsk assured osteoclast commitment of both genotypes.  B. The ratio of pS6K/tS6K 
is an additional indicator of mTORC1 activity, and its increased value in the Tsc2∆OC mutants further 
confirm mTORC1 hyperactivation. 	
Figure 9. Comparing the body morphometry of CtskCre;Tsc2fl/fl to Tsc2fl/fl mice. The body length and body 
weight of both the control Tsc2fl/fl and the mutant CtskCre;Tsc2fl/fl were recorded following euthanization and 
compared to the other in terms of sex.  For females, n=14 and for males, n=10.  There was no significant 
difference in either body length or weight in males or females. 
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The femurs of male and female Tsc2∆OC mice were analyzed by microCT and 
found to display increased trabecular bone mass and cortical thickness when compared to 
a pooled control group of wild type and heterozygous mice.  Furthermore, our data suggests 
the phenotype may be stronger in females (Figure 10).  In 3-month-old mice, the bone 
volume fraction (BV/TV) and trabecular bone marrow density (BMD) were significantly 
increased. Consistently, trabecular number (Tb.N) and trabecular thickness (Tb.Th) also 
increased accompanied by an expected decrease in trabecular spacing (Tb. Sp).  For cortical 
bones, cortical thickness (Ct.Th) and periosteal area were both significantly increased 
while cortical porosity and cortical BMD decreased.   
We also evaluated the trabecular and cortical bone of 9-month-old mice using 
microCT.  As expected, all parameters were significantly increased in Tsc2∆OC mice 
compared to the control Tsc2fl/fl samples.  More notably, the bone mass and cortical 
thickness were increased compared to the values reported for the same genotype at 3 
months of age, indicating the accumulation of bone with aging.  The progressive increase 
in bone accretion from 3 months to 9 months suggests that bone formation and 
accumulation of mass is most likely progressive throughout the lifetime of the animal.   
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 MicroCT revealed a clear increase of bone mass in the Tsc2∆OC mice structurally, 
but is not revealing vis bone quality or strength.  A similar increase in bone density is also 
seen in osteopetrotic bone that results from greatly diminished bone resorption compared 
Figure 10. CtskCre;Tsc2fl/fl mice displayed increased trabecular bone mass and cortical thickness that 
progressed with age. A,B. Trabecular BV/TV and BMD was increased in the both mutant mice in both 
females and males respectively.  Both parameters also increased in both sexes at 9 months of age compared 
to 3. C,D. The cortical thickness, periosteal circumference, and cortical BMD was also significantly 
increased in the CtskCre;Tsc2fl/fl mice.  The cortical parameters also showed a progressive increase with age 
indicating a steady gain of bone mass through life. E. A 3-dimensional example of the cortex and trabeculae 
of a 9-month-old female of each genotype.  It is clear from the images that the trabecular bone mass was 
greatly increased in the mutants as well as the cortical thickness.  
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to formation.  In this osteopathy, while the bone density is increased, it is extremely brittle, 
of poor quality, and has an increased likelihood of fracture.  To assess if our Tsc2∆OC 
samples display the hallmark brittle bone of osteopetrosis, biochemical evaluation using 
three-point bending tests was performed.  The test demonstrated that the mutant Tsc2∆OC 
femurs have increased work to fracture, meaning it a higher amount of force was required 
to fracture the bone (Figure 11).  Mechanical properties of male mutant Tsc2∆OC samples 
compared to wild type Tsc2fl/fl were calculated and analyzed by Shefelbine lab.  The 
significant increase in force needed to fracture bone demonstrates that Tsc2∆OC samples 
are stronger, unlike osteopetrotic bone, suggesting that the bone formed is of good quality.   
 
 
 
 
 
 
 
 
 
 
Figure 11. Tsc2 loss results in stronger, higher density bone. Micro three-point analysis on Our mutant 
Tsc2∆OC mice as well as the wild type Tsc2fl/fl was performed and analyzed in collaboration with the 
Shelelbine lab. A. Female Tsc2∆OC mice required a mean force of 35N to fracture while controls fractured 
at 15N.  Similarly, B. Male mice Tsc2∆OC mice fractured with about 35N of force applied while the controls 
needed on 20.  Thus, in both males and females, the bones with Tsc2 deletion required a significantly higher 
force to fracture, suggesting stronger bone. 
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3.1.d The increase in bone mass is mTORC1/Raptor-dependent 
 If deletion of Tsc2 in Cathepsin K expressing cells increases bone mass by way of 
mTORC1, we generated mice deficient in Raptor, a necessary component of mTORC1.  
Molecularly, with the deletion of Raptor, mTORC1 is no longer able to work properly and 
cannot phsophorylate its downstream targets.  Therefore, we expected the deletion of 
Raptor in these Tsc2fl/fl mice to rescue the bone phenotype as Raptor deletion suppressed 
the actions of overexpressed mTORC1.  To test this, we generated the genotypes- 
CtskCre+;Tsc2fl/fl;Raptor+/+, CtskCre+;Tsc2fl/fl;Raptorfl/+, CtskCre+;Tsc2fl/fl;Raptorfl/fl, and 
CtskCre-;Tsc2fl/fl for comparison.  Note that all mice lacking the CtskCre allele were pooled 
together regardless of Raptor presence.  Analysis of both male and female mice was 
performed at 10 weeks of age using microCT.  Body weight and length was comparable 
between the genotypes within similar sexes (data not shown).  Homozygous deletion of 
Raptor rescued high bone mass phenotype, seen in Figure 12, 13.  This is seen as the high 
bone mass is reduced, visualized by the largely significant decrease in BV/TV, TB.N, and 
Tb.Th.  Additionally, the hallmark cortical thickness of Tsc2fl/fl was slightly alleviated, 
however not to a significant degree.  A common visualized trend is that 
CtskCre+;Tsc2fl/fl;Raptorfl/fl mice is more similar to the values of the CtskCre-;Tsc2fl/fl mice, 
denoting the decrease in bone mass by mTORC1 suppression.  Furthermore, we established 
that heterozygous deletion was not sufficient to suppress mTORC1 activity as the 
CtskCre+;Tsc2fl/fl;Raptor+/+ and CtskCre+;Tsc2fl/fl;Raptorfl/+ genotypes displayed similar 
parameters.  Thus, we conclude that the high bone mass phenotype in CtskCre-;Tsc2fl/fl mice 
is mTORC1 dependent.  
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Figure 12. Homozygous deletion of Raptor suppresses the overactive mTORC1 and reduces the high bone 
mass phenotype in females. A-D. MicroCT analysis resulted in the cortical bone parameters above.  A 
common trend seen is the homozygous deleted Raptor results in a phenotype more similar to the control 
CtskCre-;Tsc2fl/fl;Raptor?/? mice than the others.  Moreover, Raptor deletion alleviates the increased cortical 
thickness, seen in the significant decrease in periosteal area. E-I. Trabecular parameters only further 
supported the claim that homozygous Raptor deletion suppresses mTORC1 activity resulting in a lower bone 
mass seen by the largely significant decreases in BV/TV, Tb.N, and Tb.Th.  MicroCT was performed on 
males and females at 10 weeks of age.  Both sexes showed significant decreases in mTORC1 activity, but 
the female data was stronger so that is what is only reported.  For Raptor+/+, n=5; Raptorf;/+, n=7; Raptor fl/fl, 
n=3; and CtskCre-, n=7. 
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Figure 13. Comparison of the 3D images concerning the deletion of Raptor. Above are the reconstructed 
3D images of the cortical and trabecular bones of various genotypes of Raptor deletion. A. The 
CtskCre:Tsc2f;/f;;Raptor=/= mice are simply expressing the intact, overexpressing mTORC1 phenotype of 
high bone mass.  It is very similar to B. the heterozygous deletion of Raptor, indicating that this is not enough 
to rescue the high bone mass.  C. Homozygous deletion of Raptor visually decreased the cortical thickness 
and trabecular bone mass of the mice, rescuing the phenotype. 
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3.1.e Decreased osteoclast function does not explain the high bone mass phenotype in 
CtskCre-;Tsc2fl/fl mice 
 Because our mice had OC-specific deletion of Tsc2, we hypothesized that the 
phenotypic increase in bone mass was due to OC dysfunction.  The cause of defective OC 
effects can be further characterized by either an absence/low number of OCs or, 
alternatively, the presence of poorly functioning ones.  To begin, we first cultured OC from 
bone marrow or spleen of Tsc2∆OC and wildtype mice.  As displayed in Figure 14.A, the 
number of TRAP-positive, multi-nucleated cells, otherwise known as OCs, formed from 
either bone marrow or spleen precursors was comparable between the two genotypes.  We 
also carried out in vivo immunohistochemistry (IHC) on each genotype with both H&E 
staining and TRAP staining (Figure 14.B) and see normal osteoclast formation in mutant 
mice. These results contributed to the previous in vitro evidence that OCs were present in 
our mutant CtskCre;Tsc2fl/fl mice at normal levels.  Therefore, the increase in bone mass 
was not due to a lack or absence of OC.  Next, to determine if the resorptive activity of 
OCs was altered in Tsc2 deficient mice we examined in vivo serum levels of the bone 
resorption marker C-terminal telopeptides (CTX-I) via ELISA.  Serum samples were 
collected via cardiac puncture to compare the in vivo CTX-I levels of Tsc2∆OC to the 
control, CtskCre-;Tsc2fl/fl.  As seen in Figure 15, the resulting levels of CTX-I were 
analogous and, therefore, there was no difference in OC resorption activity.  Thus, our 
initial hypothesis that the increased bone mass was due to dysfunctional OCs was deemed 
incorrect.   
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Figure 14. Tsc2 deletion did not affect OC number in vivo or in vitro. A. In vitro analysis of bone marrow 
and spleen OCs displayed a comparable amount of TRAP positive multinucleated OCs between genotypes. 
B. In vivo H&E and TRAP staining also showed similar OC numbers in mutant and wild type mice.  This 
evidence opposes the possibility that the increase in bone mass of Tsc2 deleted mice is due to a lack of OCs. 
Figure 15. Tsc2 deletion did not affect the activity of OC bone resorption in vivo. In vivo serum levels of 
CTX-I were compared between CtskCre+;Tsc2fl/fl and CtskCre-;Tsc2fl/flmice.  In both male and females at 3 
and 9 months of age, there was no difference in levels of the bone resorption marker.  Thus, the increase in 
bone mass was not due to OC dysfunction.  
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3.1.f Bone formation rate is increased in CtskCre+;Tsc2fl/flmice 
 Initially, we hypothesized that the increase in bone mass was due to dysfunctional 
OC either by lack of numbers or decreased resorptive ability.  Examination both in vivo 
and in vitro resulted in Tsc2 deleted cells exhibiting normal OC numbers and activity, 
disputing both options.  Thus, we had revise and state a new hypothesis.  Because the loss 
of resorptive function was not the cause of the high bone mass, the loss of Tsc2 in OCs 
may instead indirectly increase bone formation.  To analyze this theory, we utilized 
dynamic histomorphometry, a technique involving the injection of two fluorescent labels 
into the calcifying bone of the mice.  Calcein (green) and demeclocycline (red) are injected 
into the mouse intraperitoneally at different time points.  Later analysis of bone samples 
will show the labels under a microscope.  The rate of bone formation can then be calculated 
from the distance between the labels and the interval of time between injections.  We 
performed dynamic histomorphometry on both sexes of Tsc2fl/fl and Tsc2∆OC mice after 
injecting the fluorescent labels in both trabecular and periosteal bone.  We then calculated 
the bone formation rate (BFR) and mineral apposition rate (MAR), two indicators of bone 
formation and OB activity, seen in Figure 16.  In females, there was a very significant 
increase in BFR and MAR of trabecular and periosteal bone.  Males, conversely, only 
displayed increases in the BFR and MAR of cortical bone.  An increase in BFR and MAR 
suggests the possibility that OB bone formation is upregulated in Tsc2∆OC mice.   
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To further test the activity of OBs in response to the deletion of Tsc2, serum levels 
of the bone formation marker procollagen type 1 propeptides (P1NP) were analyzed in 
vivo.  Samples were collected from males and females at 3 and 9 months of age and 
analyzed via ELISA.  Tsc2∆OC mice reported significantly higher levels of P1NP, seen in 
Figure 17.  These increased results regarding increased P1NP, in addition to the reported 
increase in BFR and MAR, suggest that Tsc2 deletion resulted in increased OB activity and 
enhanced bone formation.   
 
Figure 16. Dynamic histomorphometry indicated an increase in the BFR and MAR of female Tsc2∆OC 
mice. A. We performed dynamic hystomorphetric analysis on our Tsc2∆OC and control mice.  Injection of 
calcein was followed by injection of democlocycline as bone samples were viewed, and the calculations of 
MAR and BFR were made.  Both were significantly increased in the mutant Tsc2∆OC. B. Similar injection 
into the periosteal area of female samples were completed.  This alsoled to an increased BFR and MAR, 
clearly depicted by the definitive separation between the fluorescent labels. 
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3.2 Exploring the potential cell origin driving the high bone mass 
3.2.a Alternative Cre drivers  
 The OC-specific deletion of Tsc2 leads to an increased bone mass that is not due to 
dysfunction or absent OCs.  With Tsc2∆OC mice, bone formation rate and OB activity are 
increased, but it is still unclear if this outcome is dependent on the OC action.  Recent 
reports have suggested that Cathepsin K-Cre may also delete in other cell types, including 
osteocytes, and we thus wished to investigate whether deletion in OC or OCyte was 
responsible for the high bone mass phenotype.  To do so, we implemented the use of 
alternative Cre drivers other than Ctsk to delete Tsc2 specifically in other cell lines.  First, 
we examined the other OC lineage option, Rank-Cre, that also results in OC-specific 
deletion of Tsc2.  In the act of generating these mice, several problems arose.  Even with 
the birth of over 100 pups, the genotypes RankCre;Tsc2fl/+ and RankCre;Tsc2+/+ were the 
only to arise leading to restricted comparison.  Furthermore, the genotype proved lethal as 
Figure 17. Deletion of Tsc2 resulted in enhanced expression of the bone formation marker P1NP. Serum 
levels of 3- and 9-month-old female mice were collected via cardiac puncture.  Following serum separation, 
levels of the bone formation marker P1NP were analyzed via ELISA.  The results showed that Tsc2 deletion 
led to increased levels of P1NP in the serum, indicating an increase in bone formation.   
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pups survived only days after birth.  We instead implemented timed-mating experiments 
to collect embryonic samples prior to birth in addition to the skeleton of one day old pups 
(P1).  We analyzed the skulls of the P1 pups using microCT to assess if a phenotype was 
present, however no difference was seen at this stage (Figure 18).  
 
 
 
 
 
Next, we utilized the OCyte-specific Dmp1 Cre driver.  When crossed with Tsc2fl/fl, 
mice are generated with the genotype Dmp1Cre;Tsc2fl/fl featuring a specific deletion of 
Tsc2 in OCytes.  Analysis of the right femurs of our mouse samples were performed by 
microCT at 10 weeks of age in both males and females.  The gross body morphometry was 
comparable between genotypes within their sexes, however the appearance of the femur 
was very pale suggesting a low amount of bone marrow.  We found that the 
Dmp1Cre+;Tsc2fl/fl displayed a significantly higher bone mass compared to the the control 
Dmp1Cre-;Tsc2fl/fl mice (Figure 19, 20).  When analyzing both the cortical and trabecular 
parameters, there was a statistically significant difference between the genotypes in for 
each.  Results supporting the conclusion of high bone mass are the large increaase in 
Figure 18. MicroCT analysis of one-day-old pups showed no clear difference in bone phenotype. A. The 
skull of a one day old mouse pup with the genotype RANKCre+/+;Tsc2+/+was compared with the skull of B. 
a mouse of the same age but with the genotype RANKCreKI/+;Tsc2fl/fl.  No explicit difference was seen in 
comparing the bone phenotype of the skulls.      
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trabecular BV/TV, Tb.Th, and Tb.N with an accompanying decrease in Tb.Sp.  In terms of 
cortical bone, the Ct.Th and periosteal area were also greatly increased.    
Figure 19.  OCyte-specific deletion of Tsc2 by use Dmp1Cre results in a phenotype of significantly high 
bone mass.  A-D. MicroCT analysis resulted in the cortical bone parameters above.  A common trend seen 
is the homozygous deleted Raptor results in a phenotype more similar to the control CtskCre-
;Tsc2fl/fl;Raptor?/? mice than the others.  Moreover, Raptor deletion alleviates the increased cortical thickness, 
seen in the significant decrease in periosteal area. E-I. Trabecular parameters only further supported the 
claim that homozygous Raptor deletion suppresses mTORC1 activity resulting in a lower bone mass seen 
by the largely significant decreases in BV/TV, Tb.N, and Tb.Th.  MicroCT was performed on males and 
females at 10 weeks of age.  Both sexes showed significant decreases in mTORC1 activity, but the female 
data was stronger so that is what is only reported.  For Raptor+/+, n=5; Raptorf;/+, n=7; Raptor fl/fl, n=3; and 
CtskCre-, n=7. 
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3.2.b Assessment of bone marrow radiation chimeras 
 In addition to the selection of alternative Cre drivers, the cell of origin can 
be investigated using radiation chimera, an analysis technique involving whole body 
irradiation and the injection of donor cells.  The basic schematic for the process can be seen 
in Figure 21.  Following the general procedure for radiation chimeras, our experiment 
specifically sought to investigate if the injection of wild type bone marrow cells into an 
irradiated mutant mouse could rescue the phenotype.  We irradiated mutant mice and 
transplanted  them with either mutant or wild-type donor cells, that will differentiate into 
mature OCs.  We performed whole body radiation on 10 mice with the genotype 
Figure 20. Comparison of the 3D images of cortical and trabecular bones using an OCyte-specific Cre 
driver.  The above images are 3D reconstructions of the cortical and trabecular bone samples of osteocyte-
specific deletion of Tsc2.  A, OCyte specific deletion of Tsc2 resulted in a significantly higher bone mass 
and seen in the images.  The cortical thickness is much larger and the number and thickness of trabeculae is 
easily visualized.  B. Without the Cre-driver, the bone is not as thick. 
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CtskCre+;Tsc2fl/fl (CD45.2) when the mice were 4-5 weeks of age.  Meanwhile, bone 
marrow cells were isolated from five mice expressing a mutant genotype CtskCre;Tsc2fl/fl 
(mTmG CD45.2) or the wild type Tsc2fl/fl (CD45.1).  
 
 
 
 
 
 
 
 
 
Following the 16-week recovery, mice were analyzed by microCT while chimerism 
was confirmed via flow cytometry.  The bone parameters determined by microCT analysis 
are reported in Figure 22.  There was no bone marrow donor genotype-dependent 
difference in bone as assessed by microCT parameters,   There were no significant 
differences in any cortical paramaters, and only the Tb.Th displayed a slight increase in 
those mice receiving bone marrow from wild type donor compared to mutant donor.  
Therefore, replacement of bone marrow, and thus osteoclasts, with wild type cells did not 
Figure 21. Basic schematic of bone marrow radiation chimeras. The above diagram is a visual 
representation of the bone marrow chimerism process.  The recipient mouse with the genotype 
CtskCre+;Tsc2fl/fl was first subject to whole body radiation to completely irradicate itself of its own cell line.  
Donor cells were then isolated from a donor of either CtskCre;Tsc2fl/fl or Tsc2fl/fl genotype.  After 16 weeks 
of recovery, mice were analyzed by microCT to inquire as to a phenotype.     
  
CtskCre+;Tsc2fl/fl 
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rescue the phenotype seen in mutant mice.  From this data, we conclude that the high bone 
mass seen in CtskCre;Tsc2 mice is not solely the result of loss of Tsc2 function in OCs.   
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Figure 22. Injection of wild type donor cells into irradiated mutant recipients did not rescue the bone 
phenotype. A-D. 10 male irradiated mutant mice were injected with donor bone marrow cells from either 
another mutant or a wild-type mouse.  MicroCT analysis reported no significant difference in the cortical 
parameters of bone.  Additionally, trabecular parameters E-I., such as bone density and bone volume were 
also unchanged.  Tb.Th was only slightly increased in mice receiving wild type donor bone marrow cells.  
Overall, this data provides evidence that the phenotype can’t be rescues with wild type OCs. 
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3.3 Cthrc1 is expressed by multiple cells and is a clastokine  
3.3.a Cthrc1 expression is increased in Tsc2∆OC and Dmp1Cre mice 
 Thus far, we analyzed the additional cell sources that could be driving the high bone 
mass phenotype seen in Tsc2∆OC mice.  In parallel to investigating the cell of origin for 
the high bone mass phenotype, we also investigated whether mutant OC might be 
influencing the actions of OB via altered production of clastokines, or OC-derived 
cytokines.  As previously stated, one very important clastokine example is CTHRC1, a 
secreted glycoprotein that has been shown to stimulate OB activity.  Because of this role, 
we investigated the possibility that this molecule was involved in the increased bone mass 
seen with Tsc2 deletion in OCs.  First, we quantified the mRNA expression and protein 
levels of CTHRC1 in 3-month-old male mice, as well as the protein expression.  In each 
case, the levels of CTHRC1 were greatly increased in Tsc2∆OC mice compared to their 
wild type Tsc2fl/fl littermates, seen in Figure 23A,B.  In addition, we performed IHC on 
paraffin-embedded femurs and stained Cthrc1.  Analysis of the staining displayed 
expression levels of Cthrc1 by OCtyes was greatly increased with Tsc2 deletion as shown 
in Figure 23C.  The expression of Cthrc1 in OCtyes was surprising, as it was proposed to 
be made by OCs.  It is clear, especially from the enhanced image, that there is a higher 
number of Cthrc1-expressing OCytes in the Tsc2 deleted bone slices.  Furthermore, the 
staining is more intense in the Cthrc1-positive cells of Tsc2∆OC compared to the wild-
type indicating that even if cells from each genotype are expressing Cthrc1, the mutant are 
expressing it more.  Since our Dmp1Cre+;Tsc2fl/fl  mice exhibited significantly high bone 
mass, we next asked whether   mRNA levels of Cthrc1 were increased in a similar manner 
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as to the Tsc2∆OC mice and found the levels of Cthrc1 to also be high in Dmp1Cre mice, 
seen in Figure 23D.   
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.3.b The high bone mass phenotype does not appear to be Cthrc1-dependent 
 Earlier, we used a specific mouse genotype to determine that the high bone mass in 
Tsc2fl/fl mice is mTORC1-dependent.  We then applied the same theory to investigate if 
Cthrc1 is at all involved in the phenotype.  To do so, we crossed Cthrc1-/- mice to the 
Figure 23. Expression of Cthrc1 levels was increased in the mRNA and OCytes of Tsc2∆OC mice. A. The 
mRNA and protein levels of Cthrc1 in wild type Tsc2fl/fl and mutant CtskCre;Tsc2f;/f; mice were analyzed by 
q-PCR.  In each, the mutant Tsc2∆OC displayed much higher levels of Cthrc1. B. IHC staining for Cthrc1 
resulted in a higher number of OCtyes abundantly expressing Cthrc1 in Tsc2∆OC samples compared to wild 
type. 
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CtskCre;Tsc2fl/fl to generate the following genotypes- CtskCre+;Tsc2fl/fl;Cthrc1+/+, 
CtskCre;Tsc2fl/fl;Cthrc1+/-, CtskCre;Tsc2fl/fl;Cthrc1-/-, and CtskCre-.  Note that all mice 
lacking the CtskCre- allele were pooled together regardless of Cthrc1 presence.  Analysis 
by microCT was done on both male and female mice at 10 weeks of age.  The microCT 
results of female mice, shown in Figure 24 and 25, do not display any difference in bone 
phenotype correlating with  Cthrc1 genotype.  The usual tell-tale parameters such as 
BV/TV, Tb.Tb, and Ct.Th give no distinct suggestion as to the role of Cthrc1 in the high 
bone mass of Tsc2 deleted mice.  Thus, these results do not support the hypothesis that 
increased Cthrc1 might mediate the increase in bone seen in the Tsc2 knockouts.    
 
 
 
 
 
 
 
 
 
 
 
Figure 24. Comparison of the 3D cortical and trabecular bone of Cthrc1 wildtype and knockout. Above 
is a 3D reconstruction of the cortical and trabecular bone of mouse samples using microCT analysis. A. The 
control CtskCre;Tsc2f;/fl-;Cthrc1=/=mouse is seen and is indistinguishable from the Cthrc1 knockout seen in 
B. 
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3.3.c Tsc2 inhibits the expression of Ctsk and Cthrc1 
 Returning to our initial TSC mouse model, Tsc2∆OC, we have shown hat the 
resulting phenotypic increase in bone mass was not due to a lack of OC number or a 
Figure 25.  MicroCT analysis of CtskCre;Tsc2fl/fl; Cthrc1-/-mice displayed inconclusive results.  A-D. The 
results of microCT analysis of 10-week-old female mice is displayed.  The cortical parameters reveal no 
distinct phenotype or significant trend that is due to dependence on Cthrc1.  E-I. The trabecular parameters 
also did not yield significant results.  
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decrease in OC function.  We initially utilized CtskCre as it would specifically delete the 
Tsc2 in mature OCs, but the lack of evidence supporting alteration in OC function raises 
the possibility that another cell is involved entirely.  Previous studies have reported 
CtskCre deletion in the OCtytes of lactating mice.  Thus, we assessed if CtskCre deleted in 
the OCytes in mice with Tsc2 deletion.  We performed IHC staining for GFP on the femurs 
of mice with four different genotypes, CtskCre+;Tsc2fl/fl;ROSA26mT/mG, 
CtskCre+;ROSA26mT/mG, CtskCre-;Tsc2fl/fl;ROSA26mT/mG, and CtskCre-;ROSA26mT/mG.  In the 
presence of Cre, the ROSA26mT/mG allele will recombine to express GFP.  Seen in Figure 26 
A-D, Cre-recombination, as assessed by anti-GFP staining, was observed in the OCs of 
CtskCre+ femurs as expected.  However, the OCytes of the same genotypes also exhibited 
clear evidence of recombination, seen as the brown-staining cells embedded in the matrix. 
GFP positive OCytes, and thus Ctsk-Cre activity, is qualitatively increased in the absence 
of Tsc2. To examine the question of whether Ctsk expression itself might be regulated by 
the TSC complex, q-PCR analysis of Ctsk mRNA levels was performed on mouse 
embryofibroblasts (MEF) deficient for either Tsc1 or Tsc2 was compared to the same MEF 
line complemented by Tsc1/2.  A significant increase in Ctks expression was seen in MEF 
with deletion of either Tsc1 or Tsc2  (Figure 26 E, F).  Similarly, we examined the levels 
of Cthrc1 following independent deletions of Tsc1 and Tsc2.  In both instance, the mRNA 
levels of Cthrc1 significantly increased regardless of which component of Tsc1-Tsc2 was 
deleted.  The increased levels of Ctsk and Cthrc1 suggests  the possibility that the loss of 
one Tsc2 allele promotes Ctsk expression, thus driving the Ctsk expression and making 
complete deletion of Tsc2 in OCtyes more efficient.    
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Figure 26. Deletion of either Tsc1 or Tsc2 results in increased Ctsk expression. A-D. Mice were generated 
with either deletion Tsc2 and/or the presence of Ctsk.  IHC staining revealed that recombination was 
surprisingly observed in OCytes.  E,F. mRNA expression of Ctsk were analyzed in the femurs of mice 
following deletion of either Tsc1 or Tsc2.  Levels were greatly increased in the Tsc deleted mice, indicating 
that the Tsc1-Tsc2 complex negatively regulates Ctsk. 
 
	
	
	
	
	
	
50	
 
DISCUSSION 
4.1 The high bone mass phenotype of Tsc2fl/fl mice is mTORC1 dependent 
	 Tuberous sclerosis complex is an autosomal dominant disorder caused by a genetic 
mutation in either one of the genes that comprise the TSC1-TSC2 complex.  The incidence 
at birth for TSC is 1 in 6,000 with majority of initial diagnosis occurring in patients under 
15 months of age31.  Clinically, TSC patients present with benign, tumor-like lesions in 
several organ systems, most notably in the brain, kidnys, lungs, and skin.  Additional 
medical problems are associated with TSC such as lymphangioleiomyomatosis in the lung 
and angiomyolipomas in the kidney.  This latter feature eventually progresses to renal 
failure, the leading cause of death in adult patients.  Sclerotic bone lesions are very 
frequently found in the posterior vertebral elements of TSC patients (~80-90% of patients) 
but are asymptomatic so not included in the diagnostic criteria.  Molecularly, the TSC1-
TSC2 pathway is involved in the negative regulation of the mechanistic target of rapamycin 
(mTOR).  mTOR, an evolutionary-conserved kinase, is comprised of two distinctly 
functioning complexes-mTORC1 and mTORC2.  Specifically, activation of mTORC1 
leads to the phosphorylation of many downstream targets that together result in the increase 
of cell growth and protein synthesis while suppressed autophagy.  Therefore, in a mutation 
of the TSC1-TSC2 complex, such as in TSC, mTORC1 activity is unregulated leading to 
its constitutive overexpression and the increase in cellular growth2,32.   
 A unique quality of TSC is the fact that its clinical features span so many organ 
systems.  To date, there is no cure for TSC and the exact mechanisms driving the various 
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clinical features seen due to the mutation.  A mouse model of the disease was generated 
carrying heterozygous deletion in Tsc2.  Examination of the resulting mouse disease-state 
showed that they mimicked tumors in various organs, especially in the kidney.  
Additionally, analysis by microCT revealed the presence of sclerotic bone lesions in the 
Tsc2f;/f; mice in locations similar to human patients.  To further evaluate the mouse model, 
Tsc2 was specifically deleted in osteoclasts, the bone resorbing cells, using the Cre driver 
Ctsk.  Resulting mutant mice were of the genotype CtskCre;Tsc2fl/fl (Tsc2∆OC).  To 
confirm Tsc2 deletion and subsequent mTORC1 upregulation, we cultured bone marrow 
and splenocytes of mutants and controls in cytokines known to be necessary for osteocyte 
differentiation (M-CSF and RANKL).  Western blot analysis confirmed increased levels 
of downstream targets of mTORC1 (S6K and 4E-BP1) in the Tsc2∆OC mice, proving 
evidence of increased mTORC1 activity.  Next, we examined male and female mutant and 
control mice via microCT at 3 months of age and found the Tsc2∆OC to exhibit very high 
bone mass.  Bone parameters describing cortical thickness as well as trabecular bone 
density were significantly increased in the mutant Tsc2∆OC samples when compared to 
their control littermates.  Furthermore, we analyzed the similar cohorts of mice at 9 months 
of age and compared the results by sex and genotype.  Interestingly, the bone mass was 
even more greatly increased in the 9-month-olds compared to their 3-month-old 
complements, suggesting that the progressive increase in bone mass is a life-long 
occurrence.  Pathologically, osteopetrosis is a disease wherein decreased bone resorption 
compared to bone formation results in a high bone mass of brittle, poor quality bone.  To 
assess whether the high-density bone of our Tsc2∆OC mice exhibited a similar low quality 
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bone, femurs were subject to biomechanical testing by way of a micro three-point-bending.  
Interestingly, out mutant bones required more force to fracture, indicating stronger bone 
than the controls.   
 We then wanted to confirm that high bone mass resulting from Tsc2 deletion was 
occurring via mTORC1 action and not another independent pathway.  To do so, we 
generated mice with a deletion of Raptor, a necessary component of mTORC1.  We 
hypothesized that the high bone mass in Tsc2 deleted mice would be decreased to normal 
values with the deletion of Raptor as its deletion would inhibit the actions of overactive 
mTORC1.  Analysis by microCT confirmed our thinking, as both cortical and trabecular 
bone parameters of CtskCre;Tsc2fl/fl;Raptorfl/fl mice were comparable to the pooled mice of 
CtskCre-;Tsc2flfl.  Our data also concluded heterozygous deletion was not sufficient to 
suppress mTORC1 activity as the CtskCre+;Tsc2fl/fl;Raptor+/+ and 
CtskCre+;Tsc2fl/fl;Raptorfl/+ genotypes were similar to one another.  We therefore concluded 
that the phenotypic high bone mass resulting from Tsc2 deletion was mTORC1-dependent.   
 To further analyze the mechanism by which osteoclast-specific deletion of Tsc2 
increased bone mass to such an extent, we hypothesized that it was the result of osteoclast 
dysfunction.  This dysfunction could be due to either an absence or lack of osteoclasts 
numbers or from their inability to properly resorb bone.  To first examine osteoclast 
number, we performed both in vitro and in vivo analysis on osteoclasts of the mutant 
Tsc2∆OC mice and their control littermates.  In vitro histomorphometry resulted in equal 
numbers of TRAP-positive multinucleated osteoclasts between the genoypes while in vivo 
immunohistochemistry (IHC) with H&E staining and TRAP staining also showed 
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comparable numbers.  Therefore, the number of osteoclasts was not affected in the mutant 
osteoclast-specific Tsc2 deleted mice.  To test osteoclast activity, we examined in vivo 
serum levels of the bone resorption marker c-terminal telopeptides (CTX-I) and found 
similar results between the mutants and control samples.  Thus, osteoclast activity was also 
not affected in Tsc2∆OC mice therefore rejecting our hypothesis.  Next, we shifted our 
attention to the activity of the osteoblasts, the bone forming cells, and the possibility of 
indirect stimulation of bone formation resulting from osteoclast-specific Tsc2 deletion.  
Analysis by dynamic histomorphometry reported a significantly increased bone formation 
rate and mineral apposition rate by the mutant bones.  Additionally, in vivo serum levels of 
the bone formation marker procollagen type 1 propeptides (P1NP) were elevated in 
Tsc2∆OC samples.  This data together indicated an increase in osteoblast activity due to 
Tsc2 deletion.  However, inquiries remain to be answered regarding osteoblast activity and 
if the increase is due to the osteoclast-specific deletion of Tsc2 or because of an 
independent, intrinsic pathway in osteoblasts.  Further investigation is required.   
4.2 Exploring the potential cell origin driving the high bone mass 
	 Our initial hypothesis regarding the dysfunction of osteoclasts resulting in their 
Tsc2 deletion was rejected as both their number and activity were at normal levels to their 
control littermates.  This then led us to question what cell was driving the significantly 
increased bone mass seen in osteoclast-specific deletion of Tsc2.  To test this, we first 
considered the alternative osteoclast-specific Cre driver RANK.  Unfortunately, the survival 
rate of these mice was extremely poor as most did not live past a few days following birth.  
Additionally, only two genotypes could be generated even after multiple crosses and litters 
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born.  We performed time-mating experiments instead to gather data of mice ages E14, 
E18, and 1 day old pups (P1).  MicroCT analysis was performed on the skulls of the P1 
pups, but no phenotype could be discerned in comparing the genotypes. However, as the 
bone phenotype of CtskCre;Tsc2fl/fl mice does not become apparent until 5 weeks of age, 
we cannot rule out that Tsc2 deletion in OC would generate a bone phenotype. The cause 
of early lethality in the RANK-Cre;Tsc2fl/fl mice is not known. However, as RANK is 
expressed in erythromyeloid progenitors of tissue resident macrophages during 
embryogenesis, lethality may be due to loss of Tsc2 in tissue resident macrophages, such 
as the glia and Kupfer cells of the liver64. 
 Next, we crossed the osteocyte-specific Cre driver Dmp1 to Tsc2fl/fl mice.  The 
resulting mice were analyzed at 10 weeks of age via microCT.  We observed a high bone 
mass phenotype similar to that seen with CtksCre;Tsc2fl/fl mice. As Cathepsin K 
expression has increasing been reported in OCytes, this raises the possibility that the 
increased bone formation and high bone mass phenotype we observe is due to  deletion of 
Tsc2 in OCytes rather than OC.  Keeping the hallmark dense but brittle bone of 
osteopetrosis in mind, the clear next step is to test the biomechanical properties of this 
genotype by micro three-point-bending to assess the bone strength.  This is planned to be 
done in the near future.   
 An additional approach to investigate the cellular origin of the high bone mass was 
to generate radiation chimera.  Wild-type bone marrow was unable to rescue the mutant 
phenotype, suggesting that the genotype of the OC is not sufficient to explain the high boen 
mass phenotype, and thus loss of Tsc2 in a second cell type is required to cause high bone 
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mass. We next need to demonstrate that the mutant phenotype cannot be transferred by 
mutant bone marrow to confirm that osteoclasts are not sufficient for the phenotype, an 
experiment that is planned in the near future.     
4.3 Cthrc1 is expressed by osteocytes and is increased in mice lacking Tsc2 
	 Initially, we investigated the role of Cthrc1 expression in the high bone mass as it 
was previously proposed to play a role in the coupling of OC to OC.  The idea was that 
Cthrc1 was a OC-derived cytokine, or clastokine, that contributed to the regulation of bone.  
Thus, we hypothesized it to be a candidate of explanation as to why the loss of Tsc2 resulted 
in high bone mass.  However, IHC staining revealed that OCytes, and not OCs, express 
Cthrc1, contradicting the work done by Kyoto University in Japan27.  Regardless of its 
specific cell of origin, Cthrc1 is believed to play an anabolic role in bone formation.  In 
our studies, we found Cthrc1 expression to be increased in CtskCre;Tsc2fl/fl mice as well as 
Dmp1Cre+;Tsc2fl/fl mice.  Therefore, we asked if Cthrc1 could possibly mediate the high 
bone mass observed in both genotypes.  We generated Cthrc1 knockouts on the 
CtskCre;Tsc2 background and, disappointingly, did not report any abrogation of the 
phenotype as we had hoped.  The lack of observed phenotype of the observed  
CtskCre;Tsc2fl/fl;Cthrc1-/- mice does not support our hypothesis that Cthrc1 is central to the 
mechanism.  However, this conclusion must be reported and interpreted cautiously.  Germ-
line knockout of Cthrc1 may potentially allow the development of compensatory 
mechanisms.  Moreover, as Cthrc1 may also possess endocrine and paracrine functions, its 
germline knockout may result in loss of both.  Thus, it may be more advantageous to delete 
Cthrc1 only in cells lacking Tsc2.  To more precisely test the role of Cthrc1 in mediating 
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the phenotype, we plan to cross Dmp1Cre;Tsc2 mice and CtskCre;Tsc2 mice to Cthrc1f;/f; 
allele.   
4.4 Conclusions  
	 The skeleton is a highly dynamic structure with crucial roles in locomotion, 
stability, and immune response.  Maintenance is the bone homeostasis is therefore 
imperative to the health of the bone and is achieved by the concerted actions of the three 
main bone cells- osteoclasts, osteoblasts, and osteocytes.  An imbalance in communication 
or activity at any point in the formation or remodeling of bone can lead to pathologies such 
as rheumatoid arthritis or osteoporosis that result in painful, limited movement.  Additional 
pathologies can result from genetic mutations and incorporate bone with associated clinical 
features in additional body systems.  Here we  have genetically manipulated of the TSC-
mTORC1 signaling pathway in OC and OCytes and found that this pathway regulates bone 
mass. Further investigation of the mechanism driving bone formation in these mutants may 
identify new therapeutic targets for bone diseases. Furthermore, this study was initially 
motivated by the observation that TSC patient almost uniformly develop sclerotic bone 
lesions, and based on our observation of increased bone in mice lacking Tsc2 in OCytes, 
we can hypothesize that these lesions may arise from focal loss of heterozygosity in 
OCytes. 
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